PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Lorenzini, T.* ; Cadilha, B.L.* ; Obeck, H.* ; Benmebarek, M.R.* ; Märkl, F.* ; Michaelides, S.* ; Strzalkowski, T.* ; Briukhovetska, D.* ; Müller, P.J.* ; Nandi, S.* ; Winter, P.* ; Majed, L.* ; Grünmeier, R.* ; Seifert, M.* ; Rausch, S.* ; Feuchtinger, T.* ; Endres, S. ; Kobold, S.

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy.

Br. J. Cancer 129, 696-705 (2023)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Background: In many situations, the therapeutic efficacy of CAR T cells is limited due to immune suppression and poor persistence. Immunostimulatory fusion protein (IFP) constructs have been advanced as a tool to convert suppressive signals into stimulation and thus promote the persistence of T cells, but no universal IFP design has been established so far. We now took advantage of a PD-1-CD28 IFP as a clinically relevant structure to define key determinants of IFP activity. Methods: We compared different PD-1-CD28 IFP variants in a human leukemia model to assess the impact of distinctive design choices on CAR T cell performance in vitro and a xenograft mouse model. Results: We observed that IFP constructs that putatively exceed the extracellular length of PD-1 induce T-cell response without CAR target recognition, rendering them unsuitable for tumour-specific therapy. IFP variants with physiological PD-1 length ameliorated CAR T cell effector function and proliferation in response to PD-L1+ tumour cells in vitro and prolonged survival in vivo. Transmembrane or extracellular CD28 domains were found to be replaceable by corresponding PD-1 domains for in vivo efficacy. Conclusion: PD-1-CD28 IFP constructs must mimic the physiological interaction of PD-1 with PD-L1 to retain selectivity and mediate CAR-conditional therapeutic activity.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
8.800
1.928
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Cd28 Costimulation; Pd-1; Blockade; Children; Efficacy; Express
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 0007-0920
e-ISSN 1532-1827
Journal British Journal of Cancer BJC
Quellenangaben Volume: 129, Issue: 4, Pages: 696-705 Article Number: , Supplement: ,
Publisher Nature Publishing Group
Publishing Place Campus, 4 Crinan St, London, N1 9xw, England
Reviewing status Peer reviewed
Institute(s) Unit for Clinical Pharmacology (KKG-EKLiP)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Immune Response and Infection
PSP Element(s) G-522100-001
DOI 10.1038/s41416-023-02332-9
WOS ID 001022796800002
Scopus ID 85163731484
PubMed ID 37400680
Erfassungsdatum 2023-10-18
[➜Report correction]